OBJECTIVE: To compare the efficacy of latanoprost, bimatoprost and travoprost for controlling IOP. METHODS: Randomized trials were identified on Medline and Embase using the following key words: glaucoma, ocular hypertension (OHT), randomization, trial, latanoprost, bimatoprost and travoprost. The studies had to compare at least two prostaglandins in monotherapy. Cross-over experimental designs were excluded. IOP at baseline and final visit, age, gender, race and period of follow-up were collected. Main outcome measure was IOP at final visit. Statistical analyses included random effects pooled estimates of treatment effects, tests for publication bias, and random-effects models to obtain adjusted treatment effects on final IOP after controlling for baseline IOP, and duration of follow-up. We also estimated the number of responders (IOP < 18mmHg) based on mean IOP value, standard deviation, and sample size. Random effects Poisson regression models were used to estimate the adjusted effects of treatments on response rates. RESULTS: A total of 224 papers were identified, including 15 randomized clinical trials. Nine studies were used in the analysis. Patient age varied from 56.7 to 68.8 years and baseline IOP ranged from 22.3 to 26.5 mmHg. At total of 378 patients were treated with bimatoprost, 385 with travoprost and 555 with latanoprost. Patients treated with travoprost and bimatoprost tended to have similarly lower IOP levels at the end of follow-up (-0.98 mmHg [95% CI: -2.08;0.13] and -1.04 mmHg [95% CI: -2.11;0.04], respectively) than those treated with latanoprost. The combined effect of newer prostaglandin analogues (bimatoprost/travoprost) was an adjusted decrease of 1.00 mmHg [95% CI: -1.91;-0.10], or a 17% higher adjusted response rate (Incidence Rate Ratio 1.17, 95% CI, 1.00–1.35, p=0.04), compared to latanoprost. CONCLUSION: Travoprost and bimatoprost may have greater efficacy in controlling IOP for patients with OHT or glaucoma.